Five years after SARS-CoV-2 first surfaced in Wuhan, China, researchers are still trying to understand long COVID. In this article, discover the latest research investigating the lasting impact of the ...

For decades, lab-made antibodies have been used to support patients fighting specific diseases. These treatments have become ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

The spike protein of the coronavirus, or SARS-CoV-2, binds to ACE2, a receptor on the host cells, which allows the virus to enter the cells and infect it. Binding is the first step for infection, and ...

It started as a respiratory illness—or so everyone thought. But it quickly became apparent that SARS-CoV-2, the virus that causes COVID-19, was so much more.

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

Renowned computational biologist Janet Thornton discusses the potential of protein structure understanding in developing new ...

The Kyushu University researchers studied the genetic information of the novel coronavirus, which was published in January, and set their sights on a “spike protein” shaped like a protuberance.

The video shows two segments: one featuring commentary about a substance binding to the coronavirus surface, followed by a narration discussing vaccine spike protein structure and antibody responses.

Protein-based vaccines use the specific parts of the virus that the immune system needs to recognise in order to develop an immune response. They do not contain the whole virus or another virus. The ...

The video shows two segments: one featuring commentary about a substance binding to the coronavirus surface, followed by a narration discussing vaccine spike protein structure and antibody responses.